Edition:
India

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

16.65USD
15 Dec 2017
Change (% chg)

$0.34 (+2.08%)
Prev Close
$16.31
Open
$16.30
Day's High
$17.32
Day's Low
$16.00
Volume
474,038
Avg. Vol
60,594
52-wk High
$26.74
52-wk Low
$13.54

Latest Key Developments (Source: Significant Developments)

Kala Pharmaceuticals reports Q3 loss per share $0.56
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Kala Pharmaceuticals Inc :Kala Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.56.Kala Pharmaceuticals - ‍Top-line results from phase 3 clinical program for KPI-121 0.25% in patients with dry eye disease are expected by end of 2017​.Kala Pharmaceuticals Inc - ‍Expects that its existing cash on hand will enable it to fund operations through Q2 of 2019​.  Full Article

Kala Pharmaceuticals submits new drug application for Inveltystm
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Kala Pharmaceuticals Inc :Kala pharmaceuticals submits new drug application to U.S. Food and Drug Administration for Inveltystm (KPI-121 1 pct).  Full Article

Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 pct passive stake in Kala Pharmaceuticals Inc
Monday, 31 Jul 2017 

July 31 (Reuters) - Kala Pharmaceuticals Inc ::Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 percent passive stake in Kala Pharmaceuticals Inc as on July 20, 2017 - Sec Filing‍​.  Full Article

Kala Pharma sees IPO of 6 mln shares priced between $14-$16/shr
Monday, 10 Jul 2017 

July 10 (Reuters) - Kala Pharmaceuticals Inc ::Kala Pharmaceuticals sees IPO of 6 million shares of co's common stock priced between $14.00 and $16.00 per share.  Full Article

BRIEF-Kala Pharmaceuticals reports Q3 loss per share $0.56

* Kala Pharmaceuticals reports third quarter 2017 financial results and provides business update